CN Patent

CN110835320B — 二氨基嘧啶类化合物及其应用

Assigned to Jiangsu Aosaikang Pharmaceutical Co Ltd · Expires 2025-12-30 · 0y expired

What this patent protects

本发明提供了一种式I所示的二氨基嘧啶类化合物，该类化合物可作为三突变型(敏感突变/T790M/C797S)EGFR激酶抑制剂，用于预防和/或治疗肿瘤。

USPTO Abstract

本发明提供了一种式I所示的二氨基嘧啶类化合物，该类化合物可作为三突变型(敏感突变/T790M/C797S)EGFR激酶抑制剂，用于预防和/或治疗肿瘤。

Drugs covered by this patent

Zykadia (ceritinib) · Novartis

Patent Metadata

Patent number: CN110835320B
Jurisdiction: CN
Classification: —
Expires: 2025-12-30
Drug substance claim: No
Drug product claim: No
Assignee: Jiangsu Aosaikang Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.